Edition:
United States

Sarepta Therapeutics Inc (SRPT.O)

SRPT.O on Nasdaq

118.09USD
23 Apr 2019
Change (% chg)

$4.30 (+3.78%)
Prev Close
$113.79
Open
$113.98
Day's High
$118.35
Day's Low
$112.54
Volume
1,363,364
Avg. Vol
1,262,686
52-wk High
$176.50
52-wk Low
$74.51

About

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne... (more)

Overall

Beta: 1.98
Market Cap(Mil.): $8,383.60
Shares Outstanding(Mil.): 73.68
Dividend: --
Yield (%): --

Financials

  SRPT.O Industry Sector
P/E (TTM): -- 110.59 62.94
EPS (TTM): -5.42 -- --
ROI: -26.93 8.01 11.75
ROE: -39.74 8.19 12.58

Sarepta shares rise after gene therapy deal, promising data

Sarepta Therapeutics Inc beefed up its gene therapies portfolio through the purchase of its partner Myonexus Therapeutics Inc and reported positive data for a genetic disorder therapy from the privately held company, sending its shares up 9 percent on Wednesday.

Feb 27 2019

UPDATE 1-Sarepta to buy Myonexus for $165 mln in gene therapy push

Feb 27 Sarepta Therapeutics Inc said on Wednesday it would buy privately held gene therapy company Myonexus Therapeutics Inc for $165 million, moving deeper into an emerging and lucrative field within the biotech sector.

Feb 27 2019

Sarepta to buy gene therapy developer Myonexus for $165 mln

Feb 27 Sarepta Therapeutics Inc said on Wednesday it exercised its option to buy privately held gene therapy maker Myonexus Therapeutics Inc for $165 million.

Feb 27 2019

Earnings vs. Estimates